Instrument Inactif

Communiqués Weifa ASA

Actions

WEIFA

NO0010308240

Produits pharmaceutiques

Communiqués

17/10/17	Weifa : ASA - minutes of extraordinary general meeting	GL
11/10/17	Weifa : ASA announces change to its financial calendar	GL
06/10/17	Weifa : Karo Pharma AB completes voluntary offer for Weifa ASA	GL
05/10/17	Weifa : Final result of the voluntary offer for Weifa ASA	GL
03/10/17	Weifa : KARO PHARMA AB'S TAKEOVER OFFER FOR WEIFA ASA SUCCESSFUL	GL
28/09/17	Weifa : UPDATE ON VOLUNTARY OFFER FOR WEIFA ASA - ACCEPTANCES AT APPROXIMATELY 90.3 %	GL
11/09/17	Weifa ASA: Karo Pharma commences voluntary cash offer to acquire the entire issued share capital of Weifa	GL
24/08/17	Weifa ASA: mandatory notification of trade and disclosure of shareholding	GL
24/08/17	Weifa ASA: Karo Pharma AB announces a recommended voluntary cash offer to acquire all shares in Weifa ASA	GL
13/07/17	Weifa ASA: Record second-quarter revenues driven by pain and cough & cold	GL
06/07/17	Weifa ASA: Invitation to presentation of Weifa's Q2 2017 results, Thursday 13 July 2017	GL
30/05/17	Weifa ASA: Ex dividend	GL
30/05/17	Weifa ASA: Minutes from the Annual General Meeting	GL
04/05/17	Weifa ASA: Call for Annual General Meeting	GL
28/04/17	Weifa ASA: Annual Report 2016	GL
27/04/17	CORRECTION: Weifa ASA: Record first-quarter revenues driven by organic growth	GL
27/04/17	Weifa ASA: Record first-quarter revenues driven by organic growth	GL
21/04/17	Weifa ASA: Invitation to presentation of Weifa's Q1 2017 results, Thursday 27 April	GL
27/02/17	Weifa : Invitation to presentation of Weifa's Q4 2016 results	PU
16/02/17	Weifa ASA: Key dates for Weifa ASA 2016 dividend	GL
16/02/17	CORRECTION: Weifa ASA: Record-breaking fourth quarter and full year 2016, dividend proposed	GL
16/02/17	Weifa ASA: Record-breaking fourth quarter and full year 2016, dividend proposed	GL
10/02/17	Weifa ASA: Invitation to presentation of Weifa's Q4 2016 results, Thursday 16 February	GL
05/02/17	Aqualis ASA: Invitation to Q4 2016 presentation	PU
12/01/17	Weifa ASA: New license agreement with AFT Pharmaceuticals for Nordic rights to groundbreaking product line within Pain Management	GL